MeiraGTx Holdings plc

NASDAQ:MGTX

Biotechnology

Healthcare
$8.32 +5.08%

+$0.53 today

Market cap
$813.12M
Beta
1.26
P/E (TTM)
-7.4
EPS (TTM)
-$1.48
52W Low $6.07High $11.85

Volume 0.58M

Average 0.84M

MGTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

MeiraGTx Holdings plcNASDAQ: MGTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $31.98M fell 2.4% year over year, behind the +9.2% change in trailing-twelve-month research & development. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.

Context

  • Research & development amounted to 159.3% of revenue in FY2025, down 199.8 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +9.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.98M+3.8% QoQ
Last fiscal yearDec 2025
$129.62M+8.5% YoY
LTMMar 2026
$128.82M+9.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.4%——
1 year+8.5%——
3-year CAGR+14.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
129.62M USD
Year-over-year change
+8.5%
4-year CAGR
+18.1%

Research & Development vs competitors

How MGTX compares with its peers on the latest reported figures

  • MGTX's LTM Mar 2026 research & development of $128.82M is the 6th highest of the 9 companies compared; the peer median is $139.52M.
  • Its year-over-year change of +9.2% is the 5th highest of 9, against a peer median of +9.6%.
  • Research & development amounts to 161.5% of revenue for MGTX, versus a peer median of 260.4%.
MGTX Competitors Peer median
Research & Development for MGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M -21.5%-2.5%546.5%
RGNXREGENXBIO Inc.LTM Mar 2026$228.65M +12.8%-2.0%260.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$219.98M +42.7%+34.6%249.3%
SANASana Biotechnology, Inc.LTM Mar 2026$146.28M -4.6%-13.1%—
QUREuniQure N.V.LTM Mar 2026$132.76M -4.7%-10.7%733.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026$128.82M +9.2%+14.8%161.5%
KRYSKrystal Biotech, Inc.LTM Jun 2026$59.23M +6.3%+11.0%13.4%
OCGNOcugen, Inc.LTM Mar 2026$41.48M +19.1%-10.9%928.9%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$18.85M +49.9%+8.2%127.5%
Peer median (excluding MGTX) $139.52M+9.6%-2.3%260.4%

Competitors are the stored peer set for MGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.7M15.92M14.02M33.28M81.39M
Cost of Revenue00023.79M4.84M
Gross Profit37.7M15.92M14.02M9.49M76.55M
Gross Margin100.0%100.0%100.0%28.5%94.0%
Research & Development66.69M85.73M103.79M119.48M129.62M
Selling, General & Admin43.77M46.55M47.29M54.22M52.9M
Operating Expenses110.46M132.28M151.08M173.7M182.52M
Depreciation & Amortization7.87M8.6M13.73M12.83M12.61M
EBITDA(71.4M)(116.07M)(57.05M)(121.69M)(89.4M)
EBITDA Margin-189.4%-729.1%-407.0%-365.7%-109.8%
Operating Income(72.76M)(116.36M)(137.06M)(164.21M)(105.97M)
Operating Margin-193.0%-730.9%-977.8%-493.4%-130.2%
Interest Income212K777K2.27M4.15M1.82M
Interest Expense288K4.95M13.25M13.27M12.2M
Other Income / Expenses(6.8M)(13.26M)53.03M16.42M(8.23M)
Income Before Tax(79.56M)(129.62M)(84.03M)(147.79M)(114.2M)
Pre-Tax Margin-211.0%-814.2%-599.5%-444.1%-140.3%
Income Tax Expense00000
Net Income(79.56M)(129.62M)(84.03M)(147.79M)(114.2M)
Net Margin-211.0%-814.2%-599.5%-444.1%-140.3%
EPS (Basic)(1.80)(2.87)(1.49)(2.12)(1.42)
EPS (Diluted)(1.80)(2.87)(1.49)(2.12)(1.42)
Weighted Avg Shares44.14M45.18M56.49M69.82M80.43M
Weighted Avg Shares (Diluted)44.14M45.18M56.49M69.82M80.43M

MeiraGTx Holdings plc

NASDAQ:MGTX

Intrinsic Alpha fair value

Locked

Current Price

$8.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.